707 related articles for article (PubMed ID: 33724754)
21. Mismatch repair deficiency testing in clinical practice.
Buza N; Ziai J; Hui P
Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
23. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Cooke D; Corvera C; Das P; Enzinger PC; Enzler T; Fanta P; Farjah F; Gerdes H; Gibson MK; Hochwald S; Hofstetter WL; Ilson DH; Keswani RN; Kim S; Kleinberg LR; Klempner SJ; Lacy J; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Outlaw D; Park H; Perry KA; Pimiento J; Poultsides GA; Reznik S; Roses RE; Strong VE; Su S; Wang HL; Wiesner G; Willett CG; Yakoub D; Yoon H; McMillian N; Pluchino LA
J Natl Compr Canc Netw; 2022 Feb; 20(2):167-192. PubMed ID: 35130500
[TBL] [Abstract][Full Text] [Related]
24. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
25. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
Spiess PE; Agarwal N; Bangs R; Boorjian SA; Buyyounouski MK; Clark PE; Downs TM; Efstathiou JA; Flaig TW; Friedlander T; Greenberg RE; Guru KA; Hahn N; Herr HW; Hoimes C; Inman BA; Jimbo M; Kader AK; Lele SM; Meeks JJ; Michalski J; Montgomery JS; Pagliaro LC; Pal SK; Patterson A; Plimack ER; Pohar KS; Porter MP; Preston MA; Sexton WJ; Siefker-Radtke AO; Sonpavde G; Tward J; Wile G; Dwyer MA; Gurski LA
J Natl Compr Canc Netw; 2017 Oct; 15(10):1240-1267. PubMed ID: 28982750
[TBL] [Abstract][Full Text] [Related]
26. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
Gradishar WJ; Moran MS; Abraham J; Aft R; Agnese D; Allison KH; Blair SL; Burstein HJ; Dang C; Elias AD; Giordano SH; Goetz MP; Goldstein LJ; Hurvitz SA; Isakoff SJ; Jankowitz RC; Javid SH; Krishnamurthy J; Leitch M; Lyons J; Matro J; Mayer IA; Mortimer J; O'Regan RM; Patel SA; Pierce LJ; Rugo HS; Sitapati A; Smith KL; Smith ML; Soliman H; Stringer-Reasor EM; Telli ML; Ward JH; Wisinski KB; Young JS; Burns JL; Kumar R
J Natl Compr Canc Netw; 2021 May; 19(5):484-493. PubMed ID: 34794122
[TBL] [Abstract][Full Text] [Related]
27. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
Gradishar WJ; Moran MS; Abraham J; Abramson V; Aft R; Agnese D; Allison KH; Anderson B; Burstein HJ; Chew H; Dang C; Elias AD; Giordano SH; Goetz MP; Goldstein LJ; Hurvitz SA; Jankowitz RC; Javid SH; Krishnamurthy J; Leitch AM; Lyons J; Mortimer J; Patel SA; Pierce LJ; Rosenberger LH; Rugo HS; Schneider B; Smith ML; Soliman H; Stringer-Reasor EM; Telli ML; Wei M; Wisinski KB; Young JS; Yeung K; Dwyer MA; Kumar R
J Natl Compr Canc Netw; 2023 Jun; 21(6):594-608. PubMed ID: 37308117
[TBL] [Abstract][Full Text] [Related]
28. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
[TBL] [Abstract][Full Text] [Related]
29. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum.
Bartley AN; Hamilton SR; Alsabeh R; Ambinder EP; Berman M; Collins E; Fitzgibbons PL; Gress DM; Nowak JA; Samowitz WS; Zafar SY;
Arch Pathol Lab Med; 2014 Feb; 138(2):166-70. PubMed ID: 23808403
[No Abstract] [Full Text] [Related]
30. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
31. Advances in the therapy of BRAF
Jin Z; Sinicrope FA
Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
[No Abstract] [Full Text] [Related]
32. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
[TBL] [Abstract][Full Text] [Related]
33. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
[TBL] [Abstract][Full Text] [Related]
34. Promising New Agents for Colorectal Cancer.
Das S; Ciombor KK; Haraldsdottir S; Goldberg RM
Curr Treat Options Oncol; 2018 May; 19(6):29. PubMed ID: 29752549
[TBL] [Abstract][Full Text] [Related]
35. Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer.
Mohan HM; Ryan E; Balasubramanian I; Kennelly R; Geraghty R; Sclafani F; Fennelly D; McDermott R; Ryan EJ; O'Donoghue D; Hyland JM; Martin ST; O'Connell PR; Gibbons D; Winter D; Sheahan K
Eur J Surg Oncol; 2016 Nov; 42(11):1680-1686. PubMed ID: 27370895
[TBL] [Abstract][Full Text] [Related]
36. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
37. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
Baraibar I; Ros J; Mulet N; Salvà F; Argilés G; Martini G; Cuadra JL; Sardo E; Ciardiello D; Tabernero J; Élez E
Expert Rev Mol Diagn; 2020 Jul; 20(7):653-664. PubMed ID: 32552041
[TBL] [Abstract][Full Text] [Related]
38. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.
Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Chao J; Das P; Denlinger CS; Fanta P; Farjah F; Fuchs CS; Gerdes H; Gibson M; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Johung KL; Keswani RN; Kleinberg LR; Korn WM; Leong S; Linn C; Lockhart AC; Ly QP; Mulcahy MF; Orringer MB; Perry KA; Poultsides GA; Scott WJ; Strong VE; Washington MK; Weksler B; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H
J Natl Compr Canc Netw; 2016 Oct; 14(10):1286-1312. PubMed ID: 27697982
[TBL] [Abstract][Full Text] [Related]
39. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
40. NCCN Clinical Practice Guidelines in Oncology: colon cancer.
Engstrom PF; Arnoletti JP; Benson AB; Chen YJ; Choti MA; Cooper HS; Covey A; Dilawari RA; Early DS; Enzinger PC; Fakih MG; Fleshman J; Fuchs C; Grem JL; Kiel K; Knol JA; Leong LA; Lin E; Mulcahy MF; Rao S; Ryan DP; Saltz L; Shibata D; Skibber JM; Sofocleous C; Thomas J; Venook AP; Willett C;
J Natl Compr Canc Netw; 2009 Sep; 7(8):778-831. PubMed ID: 19755046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
